Wellgistics Health, Inc.
Business
Wellgistics Health, Inc. operates an integrated pharmaceutical and healthcare services ecosystem comprising a specialty pharmacy, a wholesale pharmaceutical distributor, and a digital pharmacy platform. The company supplies specialty-lite and general maintenance pharmaceuticals to independent retail pharmacies and direct-to-patient consumers, offering care coordination, medication therapy management, prior authorization, and patient financial assistance. The business serves patients, providers, pharmacies, payors, and manufacturers through vertically integrated mail-order and network pharmacy dispensing, wholesale distribution, and technology-enabled hub services across all 50 states.
Summary from 10-K filed 2026-03-20
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net revenues | 23 | 18 | — | |
| Cost of net revenues | 30 | 16 | — | |
| Gross profit (loss) | −6 | 2 | — | |
| General and administrative | 70 | 7 | 3 | |
| Sales and marketing | 1 | — | — | |
| Depreciation and amortization | 3 | 1 | — | |
| Goodwill and intangible assets impairment | 13 | — | — | |
| Total operating expenses | 87 | 8 | 3 | |
| Loss from operations | −94 | −6 | −3 | |
| Interest expense, net | −5 | −831,467 | −15,081 | |
| Loss on debt extinguishment | −3 | — | — | |
| Other income | 42,045 | 120,373 | — | |
| Total other expense, net | −8 | −711,094 | −15,081 | |
| Net loss before income taxes | −101 | −7 | −3 | |
| Provision for income taxes | — | — | — | |
| Net loss | −101 | −7 | −3 | |
| Weighted average common shares outstanding - basic | 71 | 47 | 45 | |
| Weighted average common shares outstanding - diluted | 71 | 47 | 45 | |
| Net loss per common share - basic | −1.43 | −0.15 | −0.06 | |
| Net loss per common share - diluted | −1.43 | −0.15 | −0.06 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 42,571 | 1 | 1,364 | — | |
| Inventories, net | 2 | 10 | — | — | |
| Prepaid expenses | — | 524 | — | — | |
| Deferred offering costs | — | 875,385 | — | — | |
| Total current assets | 3 | 15 | 338,364 | — | |
| Property, plant and equipment, net | 229,376 | 388,180 | — | — | |
| Capitalized software | 2 | 2 | — | — | |
| Operating lease, right-of-use-assets | 966,893 | 2 | — | — | |
| Goodwill | 14 | 16 | — | — | |
| Other intangible assets, net | 10 | 21 | — | — | |
| Note receivable | — | 139,771 | — | — | |
| Other assets | — | 1 | — | — | |
| Deposits | 85,008 | 85,008 | — | — | |
| Total assets | 30 | 57 | 338,364 | — | |
| Accrued expenses and other liabilities | 6 | 4 | 2 | — | |
| Current portion of debt obligations, net of debt discount | 11 | 12 | — | — | |
| Operating lease liabilities- current portion | 569,251 | 519,490 | — | — | |
| Total current liabilities | 30 | 38 | 3 | — | |
| Loan payable | — | 55,085 | — | — | |
| Operating lease liabilities | 527,122 | 1 | — | — | |
| Total liabilities | 43 | 51 | 3 | — | |
| Commitments and contingencies (Note 13) | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized, 102,289,619 and 51,055,508 shares issued and 101,307,498 and 51,055,508 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 10,131 | 5,105 | 4,472 | — | |
| Additional paid-in capital | 99 | 16 | −3,972 | — | |
| Accumulated deficit | −111 | −10 | −3 | — | |
| Total stockholders equity (deficit) | −12 | 7 | −3 | −5,250 | |
| Total liabilities and stockholders equity (deficit) | 30 | 57 | 338,364 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Allowances for credit losses and note receivable | 927,596 | 93,378 | — | |
| Write off of other assets | 1 | — | — | |
| Amortization of debt discount | 33,411 | — | — | |
| Stock-based compensation | 55 | 1 | — | |
| Goodwill and intangble assets impairment | 13 | — | — | |
| Reserve for obsolete inventory | 6 | — | — | |
| Depreciation | 158,804 | 67,616 | — | |
| Amortization | 3 | 1 | — | |
| Accounts receivable, net | 799,771 | −40,081 | — | |
| Inventories, net | 2 | −72,356 | — | |
| Prepaid expenses | 524 | 11,435 | — | |
| Other assets | — | −587,539 | — | |
| Accounts payable | 2 | −882,315 | 1 | |
| Accrued expenses and other liabilities | 3 | 2 | 2 | |
| Operating lease liabilities, net | 41,746 | 22,091 | — | |
| Due from / to related parties, net | 321,090 | 3 | −269,207 | |
| Net cash used in operating activities | −11 | −1 | −349,136 | |
| Cash acquired in business combinations | — | 931,368 | — | |
| Deposits for operating leases | — | −85,008 | — | |
| Investments in capitalized software | −881,526 | −377,288 | — | |
| Net cash (used in) provided by investing activities | −881,526 | 469,072 | — | |
| Proceeds from promissory note | 865,000 | — | — | |
| Repayment of seller promissory note | −137,141 | −135,777 | — | |
| Proceeds from revolving line of credit | 20 | 756,480 | — | |
| Repayment of revolving line of credit | −24 | — | — | |
| Proceeds from Merchant cash advance | 1 | 1 | — | |
| Repayment of merchant cash advance | −2 | — | — | |
| Proceeds from term loan | 2 | — | — | |
| Repayment f term loan | −652,931 | — | — | |
| Proceeds from common stock issued pursuant to equity purchase agreement | 3 | — | — | |
| Proceeds from common stock issued pursuant to IPO | 4 | — | — | |
| Proceeds from common stock issued pursuant to public offering | 5 | — | — | |
| Proceeds from exercise of warrants | 2 | — | — | |
| Proceeds from common stock issued | — | 10,000 | — | |
| Offering costs | −810,583 | −162,310 | — | |
| Net cash provided by financing activities | 11 | 2 | 350,500 | |
| Net change in cash and cash equivalents | −985,765 | 1 | 1,364 | |
| Cash paid for income taxes | — | — | — | |
| Cash paid for interest | 3 | 332,847 | — | |
| Licence acquired through accounts payable | 3 | — | — | |
| Issuance of commitment shares under equity purchase agreement | 594,320 | — | — | |
| Derecognition of promissory note and accrued interest pursuant to debt extinguishment | 16 | — | — | |
| Common stock issued in partial settlement of sellers note | 10 | — | — | |
| Common stock issued pursuant to debt settlement | 5 | — | — | |
| Assets acquired in business combinations | — | 39 | — | |
| Liabilities assumed in business combinations | — | 15 | — | |
| Common stock issued pursuant to business combinations | — | 15 | — | |
| Repayment of note payable by related party on behalf of Company | — | 250,000 | — | |
| Note payable issued pursuant to business combination | — | 15 | — | |
| Liabilities payable pursuant to business combination | — | 10 | — | |
| Shares issued pursuant to business combination | — | 15 | — | |
| Promissory note issued pursuant to business combination | — | 15 | — | |
| Debt assigned to related party | — | 250,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Wellgistics Health, Inc.'s CIK number?
Wellgistics Health, Inc.'s SEC CIK number is 0002030763 (2030763). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Wellgistics Health, Inc.'s SEC filings?
All of Wellgistics Health, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Wellgistics Health, Inc. last report earnings?
Wellgistics Health, Inc. (WGRX) most recently filed an earnings 8-K with the SEC on May 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-024454). This is Wellgistics Health, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Wellgistics Health, Inc.'s most recent earnings 8-K?
Wellgistics Health, Inc.'s latest earnings 8-K (Item 2.02) was filed May 19, 2026 under accession 0001493152-26-024454. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Wellgistics Health, Inc.'s latest earnings 8-K →
Look up any company's CIK number →